VEGFA and neoplasm: Although celecoxib has been reported as an antiangiogenic therapy as it inhibits prostaglandin-E2-dependent VEGF production [35], subsequently reducing microvessel density, tube formation and serum VEGF levels, several studies suggest that it may have contradictory effects on tumour responsiveness and angiogenesis [82,83].